Latest Materials News

Scalare Partners Holdings Limited reported a 26% increase in total revenues to $3.54 million for FY25, driven by strong growth in founder support services and strategic acquisitions. However, the Group recorded a statutory loss of $2.65 million amid increased structural and compliance costs following its ASX listing and expansion.

Far Northern Resources has confirmed a combined JORC-compliant gold resource of over 117,000 ounces across its Northern Territory and Queensland projects, with Phase 2 drilling at Bridge Creek set to commence in September 2025.

Evolution Energy Minerals has disclosed a default notice from Tanzanian regulators over delayed mining commencement, yet remains confident in retaining its key graphite mining license.

Sumitomo Corporation has committed to a strategic equity investment in Mitchell Services’ Loop Decarbonisation JV, valuing the business at $24 million and signaling confidence in its mining sector emissions solutions.

Metro Mining has delivered a striking half-year turnaround with a $119.8 million net profit, driven by record shipments, strong pricing, and significant foreign currency hedging gains.

PPK Group Limited reported a significant statutory loss for FY25, driven by a major non-cash impairment on its Li-S Energy investment, while its ballistic protection arm Craig International Ballistics delivered exceptional revenue growth.

Change Financial Limited reported a robust FY25 with 42% revenue growth and its first full-year positive underlying EBITDA, driven by strong PaaS expansion and strategic exit from the US market. The company projects further growth and profitability in FY26.

TrivarX Limited reported a reduced net loss of $943K for FY25 alongside a $3.68 million equity raise, yet flagged material uncertainty over its ability to continue as a going concern.

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

RemSense Technologies posted a 107% revenue surge to $3.44 million in FY2025 alongside a 67% reduction in net loss, driven by operational efficiencies and strong client demand. The company achieved positive cash EBITDA and strengthened its global footprint with Tier 1 clients.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Civmec Limited posted solid FY25 results with $810.6 million revenue and a strategic acquisition boosting its naval shipbuilding footprint. The company’s $1.25 billion order book and focus on low-carbon sectors set the stage for growth.